INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 152 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q2 2022. The put-call ratio across all filers is 0.31 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $144,612 | +49.9% | 7,800 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $96,486 | -11.5% | 7,800 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $109,000 | -68.4% | 7,800 | -68.8% | 0.00% | -75.0% |
| Q2 2022 | $345,000 | -15.2% | 25,000 | 0.0% | 0.01% | +14.3% |
| Q1 2022 | $407,000 | 0.0% | 25,000 | 0.0% | 0.01% | +16.7% |
| Q4 2021 | $407,000 | +9.7% | 25,000 | 0.0% | 0.01% | -14.3% |
| Q3 2021 | $371,000 | -33.6% | 25,000 | -10.7% | 0.01% | -36.4% |
| Q2 2021 | $559,000 | +507.6% | 28,000 | +600.0% | 0.01% | +450.0% |
| Q1 2021 | $92,000 | +124.4% | 4,000 | +142.4% | 0.00% | +100.0% |
| Q4 2020 | $41,000 | -18.0% | 1,650 | +37.5% | 0.00% | -66.7% |
| Q3 2020 | $50,000 | -12.3% | 1,200 | 0.0% | 0.00% | -25.0% |
| Q2 2020 | $57,000 | -25.0% | 1,200 | 0.0% | 0.00% | -42.9% |
| Q1 2020 | $76,000 | -93.3% | 1,200 | -92.9% | 0.01% | -87.3% |
| Q3 2019 | $1,128,000 | -16.6% | 17,000 | 0.0% | 0.06% | -23.6% |
| Q2 2019 | $1,353,000 | -28.9% | 17,000 | 0.0% | 0.07% | -30.8% |
| Q1 2019 | $1,902,000 | +11.0% | 17,000 | 0.0% | 0.10% | +7.2% |
| Q4 2018 | $1,713,000 | -20.3% | 17,000 | 0.0% | 0.10% | -5.8% |
| Q3 2018 | $2,148,000 | +50.6% | 17,000 | 0.0% | 0.10% | +3.0% |
| Q2 2018 | $1,426,000 | +36.3% | 17,000 | 0.0% | 0.10% | +40.8% |
| Q1 2018 | $1,046,000 | +5.3% | 17,000 | 0.0% | 0.07% | +7.6% |
| Q4 2017 | $993,000 | +0.6% | 17,000 | 0.0% | 0.07% | +2100.0% |
| Q3 2017 | $987,000 | -52.0% | 17,000 | 0.0% | 0.00% | -57.1% |
| Q2 2017 | $2,058,000 | +7.0% | 17,000 | 0.0% | 0.01% | +16.7% |
| Q1 2017 | $1,923,000 | +4.1% | 17,000 | 0.0% | 0.01% | 0.0% |
| Q4 2016 | $1,847,000 | -34.0% | 17,000 | 0.0% | 0.01% | -33.3% |
| Q3 2016 | $2,798,000 | +15.3% | 17,000 | 0.0% | 0.01% | 0.0% |
| Q2 2016 | $2,426,000 | +11.1% | 17,000 | 0.0% | 0.01% | -10.0% |
| Q1 2016 | $2,184,000 | -94.7% | 17,000 | -93.8% | 0.01% | -94.8% |
| Q4 2015 | $40,881,000 | +10.2% | 273,723 | +22.4% | 0.19% | +3.8% |
| Q3 2015 | $37,093,000 | -31.6% | 223,643 | -0.4% | 0.18% | -27.6% |
| Q2 2015 | $54,206,000 | +11.1% | 224,568 | +29.8% | 0.25% | +16.5% |
| Q1 2015 | $48,795,000 | +75.2% | 173,018 | -2.3% | 0.22% | +83.2% |
| Q4 2014 | $27,845,000 | +16279.4% | 177,018 | +34339.3% | 0.12% | +11800.0% |
| Q1 2014 | $170,000 | – | 514 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 640,688 | $9,514,000 | 1.49% |
| CM Management, LLC | 45,000 | $668,000 | 0.50% |
| EULAV Asset Management | 660,000 | $9,801,000 | 0.26% |
| DLD Asset Management, LP | 225,200 | $3,346,000 | 0.24% |
| Virtus ETF Advisers LLC | 21,387 | $318,000 | 0.14% |
| GSA CAPITAL PARTNERS LLP | 79,145 | $1,175,000 | 0.12% |
| Hennion & Walsh Asset Management, Inc. | 136,720 | $2,030,000 | 0.11% |
| ALTRINSIC GLOBAL ADVISORS LLC | 168,800 | $2,507,000 | 0.08% |
| Inspire Investing, LLC | 31,868 | $473,000 | 0.06% |
| DUALITY ADVISERS, LP | 51,196 | $760,000 | 0.06% |